Carregant...
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...
Guardat en:
| Publicat a: | Genome Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ https://ncbi.nlm.nih.gov/pubmed/30914057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-019-0631-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|